Current Hypertension Reports

, Volume 9, Issue 5, pp 368–372

Weight reduction for treatment of obesity-associated hypertension: Nuances and challenges

Article

Abstract

Weight reduction is generally recommended as the first line of treatment for the increasing problem of obesity-associated hypertension. At first glance, this recommendation seems compelling, but evidence suggests that weight loss for obesity-associated hypertension is neither simple nor consistently effective as antihypertensive therapy. First, dietary and behavioral therapy is accompanied by an extremely high rate of weight regain after loss. Mounting evidence shows that this recidivism reflects neurobiologic and not simply psychologic adaptations to dietary restriction. Second, chronic blood pressure-lowering effects of weight loss produced by diet, weight-reducing drugs, or bariatric surgery may not be as pronounced as commonly thought. Third, there is evidence that dietary restriction, independent of weight loss, reduces sympathetic nervous system activity and might thereby contribute to reducing blood pressure. This phenomenon deserves more consideration in designing and interpreting studies of blood pressure changes during diet-induced weight loss. This article reviews these issues and highlights the nuances and challenges in the effectiveness of weight loss for treatment of obesity-induced hypertension.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References and Recommended Reading

  1. 1.
    Jordan J, Engeli S, Redon J, et al.: European Society of Hypertension Working Group on Obesity: background, aims and perspectives. J Hypertens 2007, 25:897–900.PubMedCrossRefGoogle Scholar
  2. 2.
    Alexander JK, Amad KH, Cold VW: Observation on some clinical features of extreme obesity with particular reference to cardiorespiratory effects. Am J Med 1962, 32:512–524.CrossRefGoogle Scholar
  3. 3.
    Mark AL, Correia M, Morgan DA, et al.: Obesity-induced hypertension: new concepts from the emerging biology of obesity. Hypertension 1999, 33:537–541.PubMedGoogle Scholar
  4. 4.
    Correia MLG, Haynes WG, Rahmouni K, et al.: The concept of selective leptin resistance: evidence from agouti yellow obese mice. Diabetes 2002, 51:439–442.PubMedCrossRefGoogle Scholar
  5. 5.
    Rahmouni R, Morgan DA, Morgan GM, et al.: Role of selective leptin resistance in diet-induced obesity hypertension. Diabetes 2005, 54:2012–2018.PubMedCrossRefGoogle Scholar
  6. 6.
    Mark AL, Correia MLG, Rahmouni K, Haynes WG: Selective leptin resistance: a new concept in leptin physiology with cardiovascular implications. J Hypertension 2002, 20:1245–1250.CrossRefGoogle Scholar
  7. 7.
    Klein S, Fontana L, Young L, et al.: Absence of an effect of liposuction on insulin action and risk factors for coronary heart disease. N Engl J Med 2004, 350:2549–2557.PubMedCrossRefGoogle Scholar
  8. 8.
    Kanai H, Tokunaga K, Fujioka S, et al.: Decrease in intra-abdominal visceral fat may reduce blood pressure in obese hypertensive women. Hypertension 1996, 27:125–129.PubMedGoogle Scholar
  9. 9.
    Rahmouni K, Mark AL, Haynes WG, Sigmund CD: Adipose depot-specific modulation of angiotensinogen gene expression in diet-induced obesity. Am J Physiol 2004, 286:E891–E895.Google Scholar
  10. 10.
    Ramsay LE, Ramsay MH, Hettiarachchi, et al.: Weight reduction in a blood pressure clinic. Brit Med J 1978, 2:244–245.PubMedGoogle Scholar
  11. 11.
    Tuck ML, Sowers J, Dornfeld L, et al.: The effect of weight reduction on blood pressure, plasma renin activity, and plasma aldosterone levels in obese patients. N Engl J Med 1981, 304:930–933.PubMedCrossRefGoogle Scholar
  12. 12.
    Fagerberg B, Andersson OK, Isaksson, Bjorntorp P: Blood pressure control during weight reduction in obese hypertensive men: separate effects of sodium and energy restriction. Brit Med J 1984, 288:11–14.Google Scholar
  13. 13.
    Dornfeld LP, Maxwell MH, Waks AU, et al.: Obesity and hypertension: long-term effects of weight reduction on blood pressure. Int J Obes 1985, 9:381–389.PubMedGoogle Scholar
  14. 14.
    MacMahon S, Cutler J, Brittain E, Higgins M: Obesity and hypertension: epidemiological and clinical issues. Eur Heart J 1987, 8(Suppl B): 57–70.PubMedGoogle Scholar
  15. 15.
    Rocchini AP, Katch V, Schork A, Kelch RP: Insulin and blood pressure during weight loss in obese adolescents. Hypertension 1987, 10:267–273.PubMedGoogle Scholar
  16. 16.
    Schotte DE, Stunkard AJ: The effects of weight reduction on blood pressure in 301 obese patients. Arch Intern Med 1990, 150:1701–1704.PubMedCrossRefGoogle Scholar
  17. 17.
    Hypertension Prevention Trial Research Group: The Hypertension Prevention Trial; three-years effects of dietary changes on blood pressure. Arch Intern Med 1990, 150:153–162.CrossRefGoogle Scholar
  18. 18.
    The effects of nonpharmacologic interventions on blood pressure of persons with high normal levels. Results of the Trials of Hypertension Prevention. Phase 1. JAMA 1992, 267:1213–1220.Google Scholar
  19. 19.
    The Trials of Hypertension Prevention Collaborative Research Group: Effects of weight loss and sodium reduction intervention on blood pressure and hypertension incidence in overweight people with high-normal blood pressure. The Trials of Hypertension Prevention. Phase II. Arch Intern Med 1997, 157:657–667.CrossRefGoogle Scholar
  20. 20.
    Dengel DR, Galecki AT, Hagberg JM, Pratley RE: The independent and combined effects of weight loss and aerobic exercise on blood pressure and oral glucose tolerance in older men. Am J Hypertens 1998, 11:1405–1412.PubMedCrossRefGoogle Scholar
  21. 21.
    Whelton PK, Appel LJ, Espeland MA, et al.: Sodium reduction and weight loss in the treatment of hypertension in older persons: a randomized controlled trial of nonpharmacologic interventions in the elderly (TONE). JAMA 1998, 279:839–846.PubMedCrossRefGoogle Scholar
  22. 22.
    Mertens IL, Van Gaal LF: Overweight, obesity and blood pressure: the effects of modest weight reduction. Obes Res 2000, 8:270–278.PubMedGoogle Scholar
  23. 23.
    Neter JE, Stam BE, Kok FJ, et al.: Influence of weight reduction on blood pressure: a meta-analysis of randomized controlled trials. Hypertension 2003, 42:878–884.PubMedCrossRefGoogle Scholar
  24. 24.
    Aucott L, Poobalan A, Smith WCS, et al.: Effects of weight loss in overweight/obese individuals and long-term hypertension outcomes: a systematic review. Hypertension 2005, 45:1035–1041.PubMedCrossRefGoogle Scholar
  25. 25.
    Winnicki M, Bonso E, Dorigatti F, et al.: Effect of body weight loss on blood pressure after 6 years of follow-up in stage 1 hypertension. Am J Hypertens 2006, 19:1103–1109.PubMedCrossRefGoogle Scholar
  26. 26.
    Sonne-Holm S, Sorensen TIA, Jensen G, Schnohr P: Independent effects of weight change and attained body weight on prevalence of arterial hypertension in obese and non-obese men. Brit Med J 1989, 299:767–770.PubMedCrossRefGoogle Scholar
  27. 27.
    Landsberg L: Feast or famine: the sympathetic nervous system response to nutrient intake. Cell Mol Neurobiol 2006, 26:497–508.PubMedCrossRefGoogle Scholar
  28. 28.
    Landsberg L: A teleological view of obesity, diabetes and hypertension. Clin Exp Pharmacol Physiol 2006, 33:863–867.PubMedCrossRefGoogle Scholar
  29. 29.
    Mark AL: Dietary therapy for obesity is the future and pharmacotherapy is the future: a point of view. Clin Exp Pharmacol Physiol 2006, 33:857–862.PubMedCrossRefGoogle Scholar
  30. 30.
    Levin BE: The drive to regain is mainly in the brain. Am J Physiol 2004, 287:R1297–R1300.Google Scholar
  31. 31.
    Hill JO: Understanding and addressing the epidemic of obesity: an energy balance perspective. Endocr Rev 2006, 27:750–761.PubMedGoogle Scholar
  32. 32.
    Kolata G: Rethinking Thin: The New Science of Weight Loss—and the Myths and Realities of Dieting. New York: Farrar, Straus and Giroux; 2007.Google Scholar
  33. 33.
    Buchwald H, Avidor Y, Braunwald E, et al.: Bariatric surgery: a systematic review and meta-analysis. JAMA 2004, 292:1724–1737.PubMedCrossRefGoogle Scholar
  34. 34.
    Sjostrom L, Lindroos A-K, Peltonen M, et al.: Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery. N Engl J Med 2004, 351:2683–2693.PubMedCrossRefGoogle Scholar
  35. 35.
    Sjostrom CD, Peltonen M, Wedel H, Sjostrom L: Differentiated long-term effects of intentional weight loss on diabetes and hypertension. Hypertension 2006, 36:20–25.Google Scholar
  36. 36.
    Sjostrom CD, Peltonen M, Sjostrom L: Blood pressure and pulse pressure during long-term weight loss in the obese: the Swedish Obese Subjects (SOS) intervention study. Obes Res 2001, 9:188–195.PubMedCrossRefGoogle Scholar
  37. 37.
    Sharma AM, Golay A: Effect of orlistat-induced weight loss on blood pressure and heart rate in obese patients with hypertension. J Hypertens 2002, 20:1731–1735.CrossRefGoogle Scholar
  38. 38.
    Hazenberg BP: Randomized, double-blind, placebo-controlled, multicenter study of sibutramine in obese hypertensive patients. Cardiology 2000, 94:152–158.PubMedCrossRefGoogle Scholar
  39. 39.
    Birkenfeld AL, Schroeder C, Pischon T, et al.: Paradoxical effect of sibutramine on autonomic cardiovascular function in obese hypertensive patients—sibutramine and blood pressure. Clin Auton Res 2005, 15:200–206.PubMedCrossRefGoogle Scholar
  40. 40.
    Jordan J, Scholze J, Matiba B, et al.: Influence of sibutramine on blood pressure: evidence from placebo-controlled trials. Int J Obes 2005, 29:509–516.Google Scholar
  41. 41.
    Scholze J, Grimm E, Herrmann D, et al.: Optimal treatment of obesity-related hypertension. The Hypertension-Obesity-Sibutramine (HOS) study. Circulation 2007, 115:1991–1998.PubMedCrossRefGoogle Scholar
  42. 42.
    Batkai S, Pacher P, Osei-Hyiamaan D, et al.: Endocannabinoids acting at cannabinoid-1 receptors regulate cardiovascular function in hypertension. Circulation 2004, 110:1996–2002.PubMedCrossRefGoogle Scholar
  43. 43.
    Van Gaal LF, Rissanen AM, Scheen AJ, et al.: Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in over weight patients: 1-year experience from the RIO-Europe study. Lancet 2005, 365:1389–1397.PubMedCrossRefGoogle Scholar
  44. 44.
    Pi-Sunyer FX, Aronne LJ, Heshmati HM, et al.: Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients. JAMA 2006, 295:761–775.PubMedCrossRefGoogle Scholar
  45. 45.
    Despre J-P, Golay A, Sjostrom L: Effects of rimonanbant on metabolic risk factors in overweight patients with dyslipidemia. N Engl J Med 2005, 353:2121–2134.CrossRefGoogle Scholar

Copyright information

© Current Medicine Group LLC 2007

Authors and Affiliations

  1. 1.Cardiovascular Division, Department of Internal Medicine, Center on Functional Genomics of Hypertension, Carver College of MedicineUniversity of IowaIowa CityUSA

Personalised recommendations